Publication:
Encorafenib and binimetinib followed by radiotherapy for patients with BRAF<SUP>V600</SUP>-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

No Thumbnail Available

Date

2024-07-01

Authors

Marquez-Rodas, Ivan
Alvarez, Ana
Arance, Ana
Valduvieco, Izaskun
Berciano-Guerrero, Miguel-angel
Delgado, Raquel
Soria, Ainara
Lopez-Campos, Fernando
Sanchez, Pedro
Romero, Jose Luis

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Oxford University Press
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Background. Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAF(V600)-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAF(V600)-mutant melanoma and brain metastasis (BM) and explored if radiotherapy improves the duration of response. Methods. E-BRAIN/GEM1802 was a prospective, multicenter, single-arm, phase II trial that enrolled patients with melanoma BRAF(V600)-mutant and BM. Patients received encorafenib 450 mg once daily plus binimetinib 45 mg BID, and those who achieved a partial response or stable disease at first tumor assessment were offered radiotherapy. Treatment continued until progression. Primary endpoint was intracranial response rate (icRR) after 2 months of EB, establishing a futility threshold of 60%. Results. The study included 25 patients with no BM symptoms and 23 patients with BM symptoms regardless of using corticosteroids. Among them, 31 patients (64.6%) received sequential radiotherapy. After 2 months, icRR was 70.8% (95% CI: 55.9-83.1); 10.4% complete response. Median intracranial progression-free survival (PFS) and OS were 8.5 (95% CI: 6.4-11.8) and 15.9 (95% CI: 10.7-21.4) months, respectively (8.3 months for icPFS and 13.9 months OS for patients receiving RDT). Most common grades 3-4 treatment-related adverse event was alanine aminotransferase (ALT) increased (10.4%). Conclusions. Encorafenib plus binimetinib showed promising clinical benefit in terms of icRR, and tolerable safety profile with low frequency of high-grade TRAEs, in patients with BRAFV600-mutant melanoma and BM, including those with symptoms and need for steroids. Sequential radiotherapy is feasible but it does not seem to prolong response.

Description

MeSH Terms

Proto-Oncogene Proteins B-raf
Alanine Transaminase
Progression-Free Survival
Medical Futility
Brain Neoplasms
Steroids
Adrenal Cortex Hormones

DeCS Terms

Radioterapia
Encéfalo
Supervivencia sin progresión
Inutilidad médica
Metástasis de la neoplasia
Corticoesteroides

CIE Terms

Keywords

Brain metastasis, Encorafenib and binimetinib, Melanoma, Radiotherapy, Targeted therapy

Citation

Márquez-Rodas I, Álvarez A, Arance A, Valduvieco I, Berciano-Guerrero MÁ, Delgado R, et al. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study). Neuro Oncol. 2024 Nov 4;26(11):2074-2083